TRAF1 Antikörper (AA 73-219)

Produktnummer ABIN7876674

Der Maus Monoklonal anti-TRAF1 Antikörper wird verwendet zum Nachweis von TRAF1 in Proben von Human. Er wurde validiert für ELISA.

Kurzübersicht für TRAF1 Antikörper (AA 73-219) (ABIN7876674)

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TRAF1 Antikörper ist unkonjugiert

Applikation: ELISA

Güteklasse: Carrier-free

Klon: TRAF1-3299

Produktdetails anti-TRAF1 Antikörper

Bindungsspezifität: AA 73-219

Verwendungszweck: TRAF1 Antibody / TNFR-Associated Factor 1 (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant fragment of human TRAF1 protein (within amino acids 73-219) was used as the immunogen for the TRAF1 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the TRAF1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the TRAF1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu TRAF1

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Andere Bezeichnung: TRAF1

Hintergrund: This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

UniProt: Q13077

Pathways: NF-kappaB Signalweg, Apoptose, Cell-Cell Junction Organization, Asymmetric Protein Localization